MedTrace Logo

A Study in Healthy Subjects and Mild Asthmatics to Investigate Pharmacokinetics of AZD5423 When Administered in Different Ways

NCT01310322 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2015-01-14

No results posted yet for this study

Summary

A study in healthy subjects and mild asthmatics to investigate Pharmacokinetics of AZD5423 when administered in different ways.

Conditions

Interventions

DRUG

AZD5423

solution for injection, administered as intravenous infusion Corr to total dose of 250µg AZD5423

DRUG

AZD5423

nebuliser suspension, inhaled via Spira, corr to approximately 300 µg lung deposited dose AZD5423

DRUG

AZD5423

nebuliser suspension, inhaled via I-neb, corr to approximately 300 µg lung deposited dose AZD5423

DRUG

AZD5423

nebuliser suspension to be administered orally, corr to a total dose of 1200 µg AZD5423

Sponsors & Collaborators

Principal Investigators

  • Darren Wilbraham, Dr · Quintiles Drug Research Unit at Guy's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01310322 on ClinicalTrials.gov